Source comparison
Sermorelin for Perimenopause Research — Full Comparison
Estrogen Replacement Therapy Restores estradiol to premenopausal range; modulates GH receptor sensitivity but doesn't stimulate GH secretion High. Multiple RCTs, long-term observational data Hot flashes, bone density, vaginal atrophy; does NOT restore GH pulsa
This comparison does not assign a generated winner or score.
- Estrogen Replacement Therapy
- Restores estradiol to premenopausal range; modulates GH receptor sensitivity but doesn't stimulate GH secretion
- High. Multiple RCTs, long-term observational data
- Hot flashes, bone density, vaginal atrophy; does NOT restore GH pulsatility or reverse VAT accumulation independent of estrogen
- Well-characterised; increased VTE and breast cancer risk with long-term use
- FDA-approved; widely available via prescription
- Sermorelin (GHRH analogue)
- Stimulates endogenous pulsatile GH release from pituitary somatotrophs
- Low. Pilot studies only, no Phase III data in perimenopausal cohorts
- VAT reduction, lean mass preservation, improved sleep architecture, enhanced insulin sensitivity
- Minimal in short-term studies; no acromegaly risk due to preserved feedback regulation
- Off-label; available through compounding pharmacies and research protocols
- Exogenous rhGH
- Direct pharmacologic GH administration; bypasses pituitary regulation
- Moderate for GH-deficient adults; NOT studied specifically for perimenopause
- Lean mass, VAT reduction, insulin resistance (worsens at high doses)
- High adverse event rate: carpal tunnel, glucose intolerance, joint pain; requires medical supervision
- FDA-approved for adult GH deficiency only; high cost, tightly regulated
- Lifestyle Modification (Resistance Training + Protein Intake)
- Stimulates endogenous IGF-1 and muscle protein synthesis via mechanical load
- High for body composition; limited direct data on perimenopausal GH axis
- Lean mass maintenance, metabolic rate, insulin sensitivity
- Extremely safe; no pharmacologic risk
- Universally accessible
- Bottom Line
- Sermorelin represents a mechanistically plausible bridge between doing nothing and prescribing exogenous GH. It targets the GH deficit that estrogen therapy doesn't address. But the evidence base is too thin to recommend it as standard care. Women seeking metabolic support during perimenopause should prioritise resistance training and adequate protein (1.6–2.0 g/kg/day) before considering peptide therapy. If sermorelin is used, it should be through a physician-supervised protocol with IGF-1 monitoring and sourced from a verified 503B compounding facility.